Finoriq research workspace

Annexon, Inc. (ANNX) Historical Metrics

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for. Review ANNX valuation ratios, fundamentals, and filing metrics on Finoriq.

Company Snapshot

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Company

Annexon, Inc. (ANNX)

Ticker

ANNX

Market Cap

$917.5M

Latest Price

$5.60

Industry

Biotech & Pharma

Open insider transactions

Annexon, Inc. (ANNX) Current Valuation Metrics

Static valuation preview for Annexon, Inc. (ANNX). Market data retrieved 2026-07-09. Filing currency USD.

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.